Rostislav Christov Raykov Buys 4,609 Shares of Fennec Pharmaceuticals (TSE:FRX) Stock

Key Points

• Director Rostislav Christov Raykov of Fennec Pharmaceuticals purchased 4,609 shares at an average price of C$3.38, increasing his total holdings to approximately C$9.12 million.
• Fennec Pharmaceuticals' stock is currently trading down 6.6% at C$12.40, with a market capitalization of C$345.12 million.
• The company is focused on developing Sodium Thiosulfate for preventing cisplatin-induced hearing loss, aiming to market its lead product candidate, PEDMARK.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov acquired 4,609 shares of the firm's stock in a transaction on Wednesday, October 8th. The shares were bought at an average price of C$3.38 per share, for a total transaction of C$15,578.42. Following the completion of the transaction, the director owned 2,697,927 shares of the company's stock, valued at approximately C$9,118,993.26. This trade represents a 0.17% increase in their ownership of the stock.

Fennec Pharmaceuticals Trading Down 6.6%

FRX stock traded down C$0.88 during midday trading on Friday, reaching C$12.40. 305 shares of the company traded hands, compared to its average volume of 1,007. Fennec Pharmaceuticals Inc. has a 52-week low of C$5.65 and a 52-week high of C$13.83. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. The business has a 50 day moving average of C$12.18 and a 200-day moving average of C$10.71. The firm has a market capitalization of C$345.12 million, a price-to-earnings ratio of -27.56 and a beta of 2.48.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.